Diabeloop
diabeloop.com
Actively hiring
Medical AI
Digital Therapeutics
Diabetes Devices
As featured in
View 1 job
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
Overview
Diabeloop develops closed-loop insulin delivery algorithms that adapt automatically to each person with type 1 diabetes. Founded in 2015 in Grenoble as a spin-out of the CEA research centre, its software drives certified medical devices in Europe. The system personalises dosing decisions from continuous glucose data.
News
Diabeloop and ViCentra Launch Smartphone-Controlled DBLG2 System Integrated with Kaleido Insulin Patch Pump and Dexcom G7 CGM, Now Open for Prescription
GRENOBLE, France - July 10, 2026 - Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 Automated Insulin Delivery (AID) system, fully integrated with ViCentra's Kaleido insulin patch pump and Dex
Read more
Report
Diabeloop Unveils New DBLG2 Demo App: Experience the Future of Automated Insulin Delivery Simulation
GRENOBLE, France - June 30, 2026 - Diabeloop, a pioneer in therapeutic AI, today announced the launch of a new, highly anticipated tool: the DBLG2 Demo App. Designed to make the future of diabetes management accessible to everyone, the DBLG2 Demo app is a
Read more
Report
Diabeloop Announces CE Marking and Gradual Launch of the New DBLG2 System, Integrated with Dexcom G7 CGM and ViCentra's Kaleido Insulin Patch Pump.
GRENOBLE, France - Diabeloop today announced CE marking approval and the gradual European launch of its latest Automated Insulin Delivery (AID) system, DBLG2, integrated with Dexcom G7 Continuous Glucose Monitoring (CGM) system. Available as a smartphone
Read more
Report
Diabeloop Heads to ATTD 2026: Exploring Physical Activity and Gender Dynamics in AID Systems
We are excited to announce that Diabeloop will be participating in the upcoming Advanced Technologies & Treatments for Diabetes (ATTD) 2026 conference next week. Our team will be presenting compelling new data focused on one of the most persistent challen
Read more
Report
Diabeloop DBLG2: FDA-Cleared and CE-Marked Advanced AID Algorithm Designed to manage unexpected glycemic excursions
Editor's Note: This release was updated on March 3rd, 2026 to more precisely reflect the FDA-cleared Intended Use and the specific design capabilities of the DBLG2 algorithm. Grenoble, France - March 3rd, 2026 - Diabeloop, a pioneer in therapeutic artific
Read more
Report
Diabeloop and Sequel Med Tech Enter Partnership to Integrate FDA-Cleared DBLG2 into the twiist Automated Insulin Delivery System
Companies anticipate product readiness by end of 2026 and launch in the US in 2027. Integration will give people with diabetes more choice in how they manage their diabetes care with twiist. GRENOBLE, France and Manchester, New Hampshire, U.S. - January 1
Read more
Report
Diabeloop receives FDA 510(k) clearance for DBLG2, an Automated Insulin Delivery algorithm in an App
The company confirms its status as a global reference partner for automated insulin delivery, with the validation of its DBLG2 algorithm and its predetermined Change Control Plan (PCCP) by the FDA. GRENOBLE, France - January 8th, 2026. Diabeloop announces
Read more
Report
Our CEO's reflection on Diabeloop's 2025 and Looking Ahead to 2026 for advancing Diabetes care together
As we step into 2026, I want to take a moment to reflect on what has been an exceptional year for Diabeloop, and to look ahead with confidence and ambition. We closed 2025 with a major milestone: the FDA clearance of DBLG2. This achievement is truly signi
Read more
Report
Dexcom Sensors Update and DBLG1 System: What You Need to Know
Progressive transition from Dexcom G6 to G7: Diabeloop prepares for the future while ensuring continuity of care. Our partner Dexcom recently announced the progressive phase-out of its G6 sensors in favor of the next generation, the Dexcom G7. At Diabeloo
Read more
Report
Diabeloop obtains CE MDR certification for DBLG2
Diabeloop obtains CE MDR certification for DBLG2, its new generation hybrid closed-loop system for people with type 1 diabetes Diabeloop, a Grenoble (France) based company in the field of technological medical devices, has obtained this August 4, 2025 the
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Diabeloop over the last 12 months, by layer, with the share of postings for each.
Technologies in use
6
Postings analysed
1
Stack modernity
78/100
Languages
Swift
Cloud & platforms
GitHub
Developer tools
Claude Code
Fastlane
OpenAI Codex
Practices & domains
CI/CD
Sign in to see how your skills match this stack
Sign In
People
Francois Miceli
Président du conseil d’administration
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
53/100
Stable
Open positions
1
1 opened / 0 closed in 30 days
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Mobile
100% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Grenoble
Grenoble
France
HQ
1 open roles 1 posted in 90 days 100% engineering 10-50 est. staff
hires for Mobile
Jobs
In office • Full-Time • 3+ years exp • Grenoble
Swift
Claude Code
OpenAI Codex
Mobile
Fastlane
DevOps
CI/CD
GitHub
Apply
Financials
Est. Annual Revenue
$6.3M
2024
Total raised
$2.1M
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2019 | $2.1M | Details |